Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) binding site , is showing promising outcomes in early patient studies. Recent inquiry https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/